Result:Weak· Market: Flat
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 48.43 | 0.7% | 10.0% |
| Total Income | 48.85 | 0.1% | 10.1% |
| Expenditure | 47.32 | 1.3% | 9.3% |
| PBT | 1.53 | 29.6% | 29.4% |
| Net Profit | 1.11 | 57.6% | 20.8% |
| OPM | 8.93% | 4.81pp | 0.69pp |
| NPM | 2.28% | 3.10pp | 0.30pp |
| EPS | 1.15 | 57.3% | 20.7% |
Revenue -10% YoY and adjusted PAT -20.8% YoY show core business declining, a below-par quarter for a pharma company despite a modest OPM uptick.
Informational and educational content only. Not investment advice.